The estimated Net Worth of Michael Reich is at least $322 Mille dollars as of 6 January 2009. Michael Reich owns over 17,700 units of Opko Health Inc stock worth over $322,468 and over the last 17 years Michael sold OPK stock worth over $0.
Michael has made over 5 trades of the Opko Health Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Michael exercised 17,700 units of OPK stock worth $15,222 on 6 January 2009.
The largest trade Michael's ever made was exercising 195,798 units of Opko Health Inc stock on 11 April 2008 worth over $9,790. On average, Michael trades about 53,029 units every 78 days since 2007. As of 6 January 2009 Michael still owns at least 206,710 units of Opko Health Inc stock.
You can see the complete history of Michael Reich stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is 4400 BISCAYNE BOULEVARD, 15TH FLOOR, MIAMI, FL, 33137.
Over the last 17 years, insiders at Opko Health Inc have traded over $862,245 worth of Opko Health Inc stock and bought 128,867,460 units worth $425,265,065 . The most active insiders traders include Phillip Md Et Al Frost Neva..., Phillip Md Et Al Frost Gamm... e Phillip Md Et Al Frost Gamm.... On average, Opko Health Inc executives and independent directors trade stock every 4 days with the average trade being worth of $142,696. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 23 May 2024, trading 100,000 units of OPK stock currently worth $127,000.
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
Opko Health Inc executives and other stock owners filed with the SEC include: